Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer.
기술보고
1/5 보강
[INTRODUCTION] Oxaliplatin is a third-generation platinum-based chemotherapeutic agent widely used for colorectal cancer treatment.
APA
Khanra S, Roychowdhury P, et al. (2026). Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer.. Current cancer drug targets. https://doi.org/10.2174/0115680096414252251125053406
MLA
Khanra S, et al.. "Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer.." Current cancer drug targets, 2026.
PMID
41572678 ↗
Abstract 한글 요약
[INTRODUCTION] Oxaliplatin is a third-generation platinum-based chemotherapeutic agent widely used for colorectal cancer treatment. However, its therapeutic application is limited by low solubility, systemic toxicity, and poor bioavailability.
[METHODS] Solid lipid nanoparticles (SLNs) were prepared using a micro-emulsion technique and further optimized via Box-Behnken Design (BBD), considering key formulation variables including Glyceryl Monostearate, Soya Lecithin, and Tween 80. Nanoparticles were characterized by in vitro drug release, drug loading, encapsulation efficiency, zeta potential, particle size, and polydispersity index (PDI). Cytotoxic efficacy against the HT-29 colorectal cancer cell line was evaluated using the Sulforhodamine B (SRB) assay.
[RESULTS] The optimized SLN formulation exhibited a mean particle size of 115.41 nm, PDI of 0.202, and zeta potential of +23.1 mV, indicating stability and efficient cellular uptake. Drug loading and encapsulation efficiency were 10.2 ± 0.4% and 92 ± 3.2%, respectively. In vitro release studies showed sustained drug release, reaching 97% over 48 hours. Cytotoxicity as-says demonstrated enhanced efficacy of Oxaliplatin SLNs, with IC₅₀ values of 0.9751 μg/mL at 24 h and 1.168 μg/mL at 48 h, compared to free Oxaliplatin (52.95 μg/mL at 24 h and 16.33 μg/mL at 48 h).
[DISCUSSION] GMS-based SLNs optimized with Tween 80, lecithin, and DDAB exhibited ideal size, charge, and high encapsulation. FTIR and DSC analyses confirmed component compatibility. The formulation showed sustained release and enhanced cytotoxicity, highlighting its potential to improve Oxaliplatin delivery and therapeutic efficacy in colorectal cancer.
[CONCLUSION] The optimized Oxaliplatin SLNs demonstrated improved solubility, controlled release, and enhanced cytotoxicity, confirming their promise as a nanocarrier system for colorectal cancer therapy. Further in vivo studies are required to validate clinical effectiveness.
[METHODS] Solid lipid nanoparticles (SLNs) were prepared using a micro-emulsion technique and further optimized via Box-Behnken Design (BBD), considering key formulation variables including Glyceryl Monostearate, Soya Lecithin, and Tween 80. Nanoparticles were characterized by in vitro drug release, drug loading, encapsulation efficiency, zeta potential, particle size, and polydispersity index (PDI). Cytotoxic efficacy against the HT-29 colorectal cancer cell line was evaluated using the Sulforhodamine B (SRB) assay.
[RESULTS] The optimized SLN formulation exhibited a mean particle size of 115.41 nm, PDI of 0.202, and zeta potential of +23.1 mV, indicating stability and efficient cellular uptake. Drug loading and encapsulation efficiency were 10.2 ± 0.4% and 92 ± 3.2%, respectively. In vitro release studies showed sustained drug release, reaching 97% over 48 hours. Cytotoxicity as-says demonstrated enhanced efficacy of Oxaliplatin SLNs, with IC₅₀ values of 0.9751 μg/mL at 24 h and 1.168 μg/mL at 48 h, compared to free Oxaliplatin (52.95 μg/mL at 24 h and 16.33 μg/mL at 48 h).
[DISCUSSION] GMS-based SLNs optimized with Tween 80, lecithin, and DDAB exhibited ideal size, charge, and high encapsulation. FTIR and DSC analyses confirmed component compatibility. The formulation showed sustained release and enhanced cytotoxicity, highlighting its potential to improve Oxaliplatin delivery and therapeutic efficacy in colorectal cancer.
[CONCLUSION] The optimized Oxaliplatin SLNs demonstrated improved solubility, controlled release, and enhanced cytotoxicity, confirming their promise as a nanocarrier system for colorectal cancer therapy. Further in vivo studies are required to validate clinical effectiveness.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- CF10 Displays Improved Synergy with Oxaliplatin in -Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress.
- Pathological complete response in microsatellite- stable gastric cancer with liver and bulky lymph node metastases after nivolumab-based chemotherapy and surgery: a case report.
- Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.
- Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment.
- SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).
- Absolute Bioavailability of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC): Systemic Pharmacokinetics of the CRC-PIPAC-II Trial.